Cholesterol changes in smoking cessation using the transdermal nicotine system

Sharon S. Allen, Dorothy Hatsukami, Jane Gorsline

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background. Cigarette smoking is a well-known major risk factor in coronary heart disease. Smoking cessation results in a positive change in atherogenic factors. High-density lipoprotein cholesterol has been observed as increasing with smoking cessation. Since the use of nicotine transdermal replacement has become so widespread, this study examined the effect, if any, of the transdermal nicotine system on selected cardiovascular parameters in patients who were abstinent from cigarette smoking, and possible dose effect. Methods. Eight cardiovascular outcome measures were evaluated at baseline and Week 6 in both abstinent and nonabstinent patients randomized to four treatment groups; transdermal nicotine system 7 mg, 14 mg, and 21 mg per day, and placebos. Results. In abstinent patients, systolic blood pressure and heart rate decreased from baseline (while still smoking, before the start of the study) to the end of transdermal treatment, while weight increased. Similarly, HDL increased while LDL decreased and triglycerides increased. In nonabstinent patients, weight also increased from baseline to Week 6 while heart rate decreased. No other variables showed significant change. In abstinent patients, effect of nicotine dosage was observed with greater weight gain in placebo than 21 mg TTS patients and greater decrease in heart rate in placebo than 21 mg TTS patients. Conclusions. In summary, the abstinent patients showed a positive effect of smoking cessation on cardiovascular risk factors even while using the transdermal nicotine system. These findings are favorable since the transdermal nicotine system has become a useful method of nicotine replacement in smoking cessation programs.

Original languageEnglish (US)
Pages (from-to)190-196
Number of pages7
JournalPreventive Medicine
Volume23
Issue number2
DOIs
StatePublished - Mar 1994

Fingerprint

Smoking Cessation
Nicotine
Cholesterol
Heart Rate
Smoking
Placebos
Blood Pressure
Weights and Measures
HDL Cholesterol
Weight Gain
Coronary Disease
Outcome Assessment (Health Care)
Therapeutics

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Cholesterol changes in smoking cessation using the transdermal nicotine system. / Allen, Sharon S.; Hatsukami, Dorothy; Gorsline, Jane.

In: Preventive Medicine, Vol. 23, No. 2, 03.1994, p. 190-196.

Research output: Contribution to journalArticle

Allen, Sharon S. ; Hatsukami, Dorothy ; Gorsline, Jane. / Cholesterol changes in smoking cessation using the transdermal nicotine system. In: Preventive Medicine. 1994 ; Vol. 23, No. 2. pp. 190-196.
@article{88340aa3c0a640cc85e077bf673a975e,
title = "Cholesterol changes in smoking cessation using the transdermal nicotine system",
abstract = "Background. Cigarette smoking is a well-known major risk factor in coronary heart disease. Smoking cessation results in a positive change in atherogenic factors. High-density lipoprotein cholesterol has been observed as increasing with smoking cessation. Since the use of nicotine transdermal replacement has become so widespread, this study examined the effect, if any, of the transdermal nicotine system on selected cardiovascular parameters in patients who were abstinent from cigarette smoking, and possible dose effect. Methods. Eight cardiovascular outcome measures were evaluated at baseline and Week 6 in both abstinent and nonabstinent patients randomized to four treatment groups; transdermal nicotine system 7 mg, 14 mg, and 21 mg per day, and placebos. Results. In abstinent patients, systolic blood pressure and heart rate decreased from baseline (while still smoking, before the start of the study) to the end of transdermal treatment, while weight increased. Similarly, HDL increased while LDL decreased and triglycerides increased. In nonabstinent patients, weight also increased from baseline to Week 6 while heart rate decreased. No other variables showed significant change. In abstinent patients, effect of nicotine dosage was observed with greater weight gain in placebo than 21 mg TTS patients and greater decrease in heart rate in placebo than 21 mg TTS patients. Conclusions. In summary, the abstinent patients showed a positive effect of smoking cessation on cardiovascular risk factors even while using the transdermal nicotine system. These findings are favorable since the transdermal nicotine system has become a useful method of nicotine replacement in smoking cessation programs.",
author = "Allen, {Sharon S.} and Dorothy Hatsukami and Jane Gorsline",
year = "1994",
month = "3",
doi = "10.1006/pmed.1994.1026",
language = "English (US)",
volume = "23",
pages = "190--196",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cholesterol changes in smoking cessation using the transdermal nicotine system

AU - Allen, Sharon S.

AU - Hatsukami, Dorothy

AU - Gorsline, Jane

PY - 1994/3

Y1 - 1994/3

N2 - Background. Cigarette smoking is a well-known major risk factor in coronary heart disease. Smoking cessation results in a positive change in atherogenic factors. High-density lipoprotein cholesterol has been observed as increasing with smoking cessation. Since the use of nicotine transdermal replacement has become so widespread, this study examined the effect, if any, of the transdermal nicotine system on selected cardiovascular parameters in patients who were abstinent from cigarette smoking, and possible dose effect. Methods. Eight cardiovascular outcome measures were evaluated at baseline and Week 6 in both abstinent and nonabstinent patients randomized to four treatment groups; transdermal nicotine system 7 mg, 14 mg, and 21 mg per day, and placebos. Results. In abstinent patients, systolic blood pressure and heart rate decreased from baseline (while still smoking, before the start of the study) to the end of transdermal treatment, while weight increased. Similarly, HDL increased while LDL decreased and triglycerides increased. In nonabstinent patients, weight also increased from baseline to Week 6 while heart rate decreased. No other variables showed significant change. In abstinent patients, effect of nicotine dosage was observed with greater weight gain in placebo than 21 mg TTS patients and greater decrease in heart rate in placebo than 21 mg TTS patients. Conclusions. In summary, the abstinent patients showed a positive effect of smoking cessation on cardiovascular risk factors even while using the transdermal nicotine system. These findings are favorable since the transdermal nicotine system has become a useful method of nicotine replacement in smoking cessation programs.

AB - Background. Cigarette smoking is a well-known major risk factor in coronary heart disease. Smoking cessation results in a positive change in atherogenic factors. High-density lipoprotein cholesterol has been observed as increasing with smoking cessation. Since the use of nicotine transdermal replacement has become so widespread, this study examined the effect, if any, of the transdermal nicotine system on selected cardiovascular parameters in patients who were abstinent from cigarette smoking, and possible dose effect. Methods. Eight cardiovascular outcome measures were evaluated at baseline and Week 6 in both abstinent and nonabstinent patients randomized to four treatment groups; transdermal nicotine system 7 mg, 14 mg, and 21 mg per day, and placebos. Results. In abstinent patients, systolic blood pressure and heart rate decreased from baseline (while still smoking, before the start of the study) to the end of transdermal treatment, while weight increased. Similarly, HDL increased while LDL decreased and triglycerides increased. In nonabstinent patients, weight also increased from baseline to Week 6 while heart rate decreased. No other variables showed significant change. In abstinent patients, effect of nicotine dosage was observed with greater weight gain in placebo than 21 mg TTS patients and greater decrease in heart rate in placebo than 21 mg TTS patients. Conclusions. In summary, the abstinent patients showed a positive effect of smoking cessation on cardiovascular risk factors even while using the transdermal nicotine system. These findings are favorable since the transdermal nicotine system has become a useful method of nicotine replacement in smoking cessation programs.

UR - http://www.scopus.com/inward/record.url?scp=0028365514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028365514&partnerID=8YFLogxK

U2 - 10.1006/pmed.1994.1026

DO - 10.1006/pmed.1994.1026

M3 - Article

C2 - 8047525

AN - SCOPUS:0028365514

VL - 23

SP - 190

EP - 196

JO - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

IS - 2

ER -